Variability Found in PROs, Gene Expression During AML Induction Chemo
Blinatumomab-Linked ICANS Cases Higher Than Previously Reported
Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Risk Factors Determine Symptom Burden Profiles by Age Group